Data / Form D filings / Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc.: Form D filing
Neumora Therapeutics, Inc., a biotechnology company in Watertown, MA, filed a Form D with the SEC in 2023. The latest, on January 3, 2023, reports $474.4 million sold of a $474.4 million offering to 124 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 490 Arsenal Way, Suite 200, Watertown, MA, 02472
- Phone
- (857) 760-0900
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2019
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1885522
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 3, 2023 | New notice | $474,356,988 | $474,356,988 | 124 | Sep 8, 2020 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Kristina Burow | Director | |
| Matthew Fust | Director | |
| Robert Nelsen | Director | |
| Kari Stefansson | Director | |
| Paul Berns | Executive Officer, Director | |
| Stacie Weninger | Director | |
| Joshua Pinto | Executive Officer | |
| Maykin Ho | Director | |
| Alaa Halawa | Director | |
| Tamara Tompkins | Executive Officer |
Other biotechnology companies in Massachusetts that filed recently
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
Every Form D from the week of Jan 2, 2023 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Neumora Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.